NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update

ALS Phase 2b PARADIGM Trial Completed Patient EnrollmentTopline results expected in Q-4 2023Cash runway beyond topline clinical study readouts, into Q-2 2024CAMBRIDGE, Mass., Aug. 16, 2023...
-Today at 09:01 am- MarketScreener

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom , ,Neurosense Therapeutics Ltd ,Nasdaq ,Prnewswire Neurosense Therapeutics Ltd ,Linkedin ,Twitter ,Exchange Commission ,Completed Patient ,Sense Therapeutics ,Amyotrophic Lateral Sclerosis ,Scientific Agreement ,Trial Under ,Biomarker Study ,Biomarkers Summit ,Months Ended June ,Interim Unaudited Statements ,Cash Flows ,Neurosense Therapeutic ,Annual Report ,Neurosense Therapeutics ,Markets ,